Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

Completed

Phase 3 Results N/A

Summary of Purpose

The purpose of this study is to evaluate the long-term safety of AVP-923 in the treatment of Involuntary Emotional Expression Disorder (IEED) also known as Pseudobulbar Affect (episodes of uncontrolled crying and/or laughter).

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 13 July 2016.

1 Feb 2003 15 Mar 2003 1 Jun 2007 1 Jun 2007 1 Jul 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Non-Randomized
  • Masking: Open Label
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Single Group Assignment

Contacts

  • Michelle Bodien & James E. Berg Vice President Clinical & Regulatory Affairs AVANIR Pharmaceuticals 11388 Sorrento Valley Road San Diego, California 92121 Phone: (858) 622-5206 Fax: (858) 658-7448

    JBerg@avanir.com & mbodien@avanir.com